Phase 3 N=386 Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
Crohn Disease
Primary: Percentage of Participants With Clinical Remission at Week 52 — 61.0; 64.9 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=940 CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
Gout · Chronic Kidney Diseases
Primary: Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3 — 135; 165 Participants — p=<0.001
N/A N=42 Mommy-Baby Treatment for Perinatal Depression
Depressive Disorder, Major · Postpartum Depression
Primary: Change in Edinburgh Depression Scale From Baseline — 17.81; 17.9; 12.04; 11.41 units on a scale
Phase 3 N=501 Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest
Heart Arrest
Primary: Number of Participants With Return of Spontaneous Circulation — 100; 86 participants
Phase 3 N=2 Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies
Spinal Muscular Atrophy Type I
Primary: Number of Participants Who Achieved Sitting Alone for at Least 10 Seconds — 1 Participants
N/A N=81 A Smartphone-Assisted Brief Behavioral Intervention for Pregnant Women With Depression
Perinatal Depression
Primary: Change in Maternal Prenatal Depression at Baseline, Midpoint, and Posttreatment (8 Weeks) — 17.3; 16.8; 12.5; 12.1 score on EPDS — p=0.757
Phase 2 N=161 Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis
End Stage Renal Disease · Anemia
Primary: Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only — 4; 8; 7; 4 Participants — p=1.0000
N/A N=350 The COVID-19 and Healthcare Workers: An Active Intervention
Brief Video-based Intervention · Non Intervention Control
Primary: Help-seeking Behavior — 8.2; 8.5; 9.3; 8.7 units on a scale
Phase 4 N=52 XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept
Opioid Dependence
Primary: # of Participants Retained on Any Form of Community Buprenorphine (Not Randomzied tx) at Week 8 — 18; 9 Participants
Phase 4 N=256 Project OOPEN: Opioid Overdose Prevention, Education and Intervention
Opioid Overdose
Primary: Rate of Fatal Opioid Overdose — 2; 6 Participants
Phase 1 N=34 Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
Neoplasms · Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0…
Phase 1 N=19 Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Number of Patients With Dose-Limiting Toxicities (DLT) — 0; 2; 0; 0 Participants
N/A N=36 EEG Studies of Induction and Recovery From Propofol Induced General Anesthesia
Brain Activity Under Sedation
Primary: EEG Power in Alpha, Slow, and Delta Bands — 10; 0.55; 2.5 Power of alpha band (decibels)
Phase 4 N=60 Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids
Barrett's Esophagus · Obesity
Primary: Change in Serum PGE2 Levels — 4.44; -21.65 Percentage of change in serum PGE2 level
N/A N=10 EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
Metastatic Pancreatic Cancer · Unresectable Pancreatic Cancer · Metastatic Colorectal Cancer
Primary: Number of Participants With Accurate Understanding of Chemotherapy Benefits at 8-12 Weeks — 0; 0 Participants